Kazia Therapeutics Faces Nasdaq Delisting Risk After Compliance Deadline

Kazia Therapeutics ( (KZIA) ) has provided an update.

Kazia Therapeutics Limited announced that it received a staff determination letter from Nasdaq on November 12, 2025, indicating the company had not regained compliance with the Market Value of Listed Securities requirement by the deadline of November 10, 2025. As a result, Kazia plans to request a hearing before a Nasdaq Hearings Panel to demonstrate its ability to meet the listing criteria and sustain long-term compliance. The outcome of this hearing is uncertain, and the company’s securities face potential suspension or delisting from the Nasdaq Capital Market.

The most recent analyst rating on (KZIA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.

Spark’s Take on KZIA Stock

According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.

Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.

To see Spark’s full report on KZIA stock, click here.

More about Kazia Therapeutics

Kazia Therapeutics Limited is a biotechnology company focused on the development of innovative cancer therapies. The company is primarily engaged in the research and development of pharmaceutical products aimed at treating various forms of cancer, with a market focus on advancing clinical trials and regulatory approvals for its drug candidates.

Average Trading Volume: 126,086

Technical Sentiment Signal: Strong Sell

Current Market Cap: $10.47M

See more insights into KZIA stock on TipRanks’ Stock Analysis page.